Title:Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Volume: 19
Issue: 16
Author(s): M. Vavuranakis, M. G. Kariori, K. I. Kalogeras, D. A. Vrachatis, C. Moldovan, D. Tousoulis and C. Stefanadis
Affiliation:
Keywords:
cTnI, cTnT, BNP, NT-proBNP, hsCRP, cardiovascular disease, coronary syndromes, troponin, biomarker, biological molecules
Abstract: There is increasing interest in utilizing novel markers of cardiovascular disease risk and consequently, there is a need to assess
the value of their use. In this paper, we will review the role of biomarkers in acute coronary syndromes, heart failure and risk
stratification for cardiovascular events as guide for treatment scribing. In particular, high sensitivity assays for troponin evaluation detect
with greater precision patients with elevated troponin. Therefore, direct and appropriate management is succeeded in these patients with
reduction of complications due to earlier treatment, as well. Regarding heart failure, randomized trials that have evaluated biomarker
guided treatment approach have not succeeded in establishing specific results for natriuretic peptides (BNP, NT-proBNP) use in terms of
therapy guidance. Apart from them, a variety of novel or already used biomarkers, have been tested by small trials for heart failure
management, without however, managing to dominate in every day care. Finally, as far as risk stratification for cardiovascular events is
concerned, hsCRP has proved to be a strong but doubted biomarker. Therefore, lifestyle and behavioral modification remain the
cornerstone of primary prevention.